Kidney Recipient Gets HIV, From Gay Donor; Sues Hospital

A lawsuit contends a Chicago hospital didn't tell a patient her new kidney came from a homosexual donor who turned out to have hepatitis and the HIV virus.

South African cartoonist makes light of Mandela

Don't worry, Nelson Mandela can laugh at himself. At least that's the opinion of Jonathan Shapiro, South Africa's leading political cartoonist for 20 years, whose work has not shied away from ridiculing the ...

Scientists Self-Censor In Response To Political Controversy

A survey of scientists whose studies became the focus of a public debate about NIH grant funding has found that many of them engaged in self-censorship as a result of the controversy.

DRC-UGANDA: Overwhelmed relief workers struggle to provide HIV services

Violence in the eastern Democratic Republic of Congo has forced thousands of people to flee across the border into neighbouring countries, but relief workers in Uganda admit that HIV is low on the list of ...

Editor's Notes- About California's Proposition 8

I have been disturbed lately by the controversy concerning Proposition 8 in California.

Sharp pen of South African cartoonist not afraid of anti-apartheid icon Nelson Mandela

At least that's the opinion of Jonathan Shapiro, South Africa's leading political cartoonist for 20 years, whose work has not shied away from ridiculing the foibles of the anti-apartheid icon.

Who's left? Yellowjackets

And then there was Kemp. Who? The Kemp Yellowjackets, that's who. Take another look.

Non-AIDS Cancer Risk Higher for Those With HIV

People with HIV have about twice the risk of developing a non-AIDS cancer as members of the general population, a new report says.

Individuals with HIV have higher risk of non-AIDS cancers

The risk of non-AIDS cancer is higher for individuals infected with HIV than for the general population, according to a meta-analysis presented here at the American Association for Cancer Research's Seventh ...

Large-Scale Trial Of Malaria Vaccine Begins In Africa Next Year

A phase III trials of a malaria vaccine candidate developed by GlaxoSmithKline Biologicals and the Walter Reed Army Institute of Research is set to begin at 11 sites in seven African countries early next year.